<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02919787</url>
  </required_header>
  <id_info>
    <org_study_id>NorPACT-1</org_study_id>
    <secondary_id>2015-001635-21</secondary_id>
    <nct_id>NCT02919787</nct_id>
  </id_info>
  <brief_title>Nordic Pancreatic Cancer Trial (NorPACT) - 1</brief_title>
  <official_title>Nordic Multicentre Un-blinded Phase II Randomized Controlled Trial (RCT) Evaluating the Additional Efficacy of Adding Chemotherapy Prior to Resection of a Pancreatic Head Malignancy to Avoid Early Mortality in Those Ultimately Resected</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the additional effect of adding chemotherapy prior to resection of a
      pancreatic head malignancy. The patients will be randomized into two groups; surgery first
      (control group) and neoadjuvant chemotherapy (intervention). Primary endpoint is overall
      survival after resection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer is the fourth leading cause of cancer-related deaths in Europe and the
      United States. Surgical resection remains the only potentially curative treatment. However,
      the median survival of patients undergoing pancreatic resection alone is 16-23 months. The
      administration of adjuvant chemotherapy leads to an improvement in overall survival. Thus,
      completion of multimodality treatment (MMT) is the ideal goal and standard of care for
      treatment of pancreatic ductal adenocarcinoma (PDAC).

      Currently, the surgery-first (SF) strategy is the most universally accepted approach to
      resectable PDAC (and is the standard of care in Norway), but the optimal sequence of surgery
      and chemotherapy remains unclear.

      The purpose of this study is to further investigate the additional efficacy of neoadjuvant
      chemotherapy to the standard treatment for resectable cancer of the pancreatic head (surgery
      followed by adjuvant chemotherapy).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival 18 month after randomization</measure>
    <time_frame>18 month</time_frame>
    <description>Overall survival at 18 months after date of randomization (intention to treat)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall mortality at one year following commencement of allocated treatment.</measure>
    <time_frame>1 year</time_frame>
    <description>Overall mortality at one year following commencement of allocated treatment (NT or SF) for those who ultimately undergo resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>until 5 years after surgery</time_frame>
    <description>Patient will come to regular after surgery for follow-up visits regarding their disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological response</measure>
    <time_frame>Arm 1: Baseline and Arm 2; 4 weeks after baseline</time_frame>
    <description>The histopathological response of the tumor to the neoadjuvant treatment will be assessed by established scores (R0 resection and (y)pN0 disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate after surgery</measure>
    <time_frame>30 and 90 days</time_frame>
    <description>Complication rate after surgery as measured by Dindo-Clavien/ISPGS classification systems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of neoadjuvant and adjuvant chemotherapy</measure>
    <time_frame>Baseline</time_frame>
    <description>The feasibility of neo-adjuvant and adjuvant chemotherapy measured by common Terminology Criteria for Adverse Events, grade 3-5, dose reduction and dose delay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related Quality of Life</measure>
    <time_frame>until 5 years after surgery</time_frame>
    <description>Data of quality of life will be assessed by the questionnaires EORTC QLQ-30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics</measure>
    <time_frame>until 5 years after surgery</time_frame>
    <description>Data of quality of life will be assessed by the questionnaires EQ-5D</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Surgery and then postoperative adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgery and then postoperative adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>Neoadjuvant treatment</description>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatine</intervention_name>
    <description>Neoadjuvant treatment</description>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Neoadjuvant treatment</description>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pancreatic surgery</intervention_name>
    <description>All patients</description>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
    <arm_group_label>Surgery and then postoperative adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>Adjuvant treatment</description>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
    <arm_group_label>Surgery and then postoperative adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatine</intervention_name>
    <description>Adjuvant treatment</description>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
    <arm_group_label>Surgery and then postoperative adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Adjuvant treatment</description>
    <arm_group_label>Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy</arm_group_label>
    <arm_group_label>Surgery and then postoperative adjuvant chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resectable adenocarcinoma of the pancreatic head

          -  T1-3, Nx, M0 (UICC 7th version, 2010)

          -  Cytologic or histologic confirmation of adenocarcinoma

          -  Age &gt; 18 year and considered fit for major surgery

          -  Written informed consent

          -  Considered able to receive the study specific chemotherapy

        Exclusion Criteria:

          -  Co-morbidity precluding pancreaticoduodenectomy

          -  Chronic neuropathy ≥ grade 2

          -  WHO performance score &gt; 2 • Granulocyte count &lt; 1500 per cubic millimetre

          -  Platelet count &lt; 100 000 per cubic millimeter

          -  Serum creatinine &gt; 1.5 UNL (upper limit normal range)

          -  Albumin &lt; 2,5 g/dl

          -  Female patients in child bearing age not using adequate contraception, pregnant or
             lactating women • Mental or organic disorders which could interfere with informed
             consent or treatments

          -  Other malignancy within the past 5 years, except non-melanomatous skin or non-invasive
             cervical cancer

          -  Percutaneous tumor biopsy

          -  Any reason why, in the opinion of the investigator, the patient should not participate

          -  Pregnancy

          -  Breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Knut Jorgen Labori, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Knut Jorgen Labori, MD PhD</last_name>
    <phone>+4723070000</phone>
    <phone_ext>+47</phone_ext>
    <email>UXKNAB@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Svein Dueland, MD PhD</last_name>
    <phone>22934000</phone>
    <email>svedue@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Per Pfeiffer</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Pfeiffer, MD, PhD</last_name>
      <phone>+4565411590</phone>
      <email>per.pfeiffer@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ville Sallinen</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ville Sallinen, MD PhD</last_name>
      <email>ville.sallinen@helsinki.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halvdan Sørby, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N- 0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knut Jørgen Labori, MD PhD</last_name>
      <phone>+47 23070000</phone>
      <email>UXKNAB@ous-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kjetil Søreide, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tromsø University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Mortensen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Olav University Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7030</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Hofsli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svein Olav Bratlie, MD PhD</last_name>
      <phone>+46313428218</phone>
      <email>svein.olav.bratlie@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Huddinge</city>
        <zip>14157</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto Sparrelid, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bergthor Björnsson, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobby Tingstedt, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Umeå</name>
      <address>
        <city>Umeå</city>
        <zip>90737</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oskar Hemmingsson, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britt-Marie Karlsson, MDPhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 14, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2016</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Knut Jørgen Labori</investigator_full_name>
    <investigator_title>Senior Consultant HPB-surgery</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

